2 completed, 1 unknown, 1 withdrawn. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Unknown 1, Withdrawn 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Cataract Surgery: new trials by email Literature Review of Cataract Surgery trials Research Report on Cataract Surgery
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dexmedetomidine in Topical Versus Peribulbar Anesthesia for Cataract Surgery Topical dexmedetomidine, Reginal dexmedetomidine - Dexmedetomidine, Cataract Surgery | Phase 2 | Unknown | Kafrelsheikh University | 94 | 2023-07-15 | 2023-09-07 |
| PREFERENTIAL Study Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE] - Cataract Surgery, Glaucoma Surgery | Phase 2 / Phase 3 | Withdrawn | Duke University | 2020-11-01 | 2021-11-17 | |
| RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1% - Corneal Endothelial Cell Loss, Ocular Pain | Phase 2 | Completed | Biogen | 307 | 2014-05-31 | 2025-06-03 |
| Efficacy and Safety of Bromfenac Ophthalmic Solution bromfenac ophthalmic solution - Cataract Surgery | Phase 2 | Completed | Bausch & Lomb Incorporated | 568 | 2007-10-01 | 2013-02-15 |
Corneal Endothelial Cell Loss (1) · Eye Pain (1)
Corneal Diseases (1) · Eye Diseases (1) · Eye Manifestations (1) · Neurologic Manifestations (1) · Pain (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Postoperative Complications (1) · Signs and Symptoms (1)
Calcium Dobesilate (1) · Dexmedetomidine (1) · prednisolone acetate (1)
Bausch & Lomb Incorporated (1) · Biogen (1) · Duke University (1) · Kafrelsheikh University (1)
United States (2) · Egypt (1)
Leon Herndon, MD (1) · Mohammed F Algyar, MD (1) · Tim McNamara, PharmD (1)